Compare Inovio Pharmaceuticals Inc (INO) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Weibo Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $0.74 (market cap $78.55M), while Weibo Corp trades at $7.72 (market cap $1.93B). The key difference: Weibo Corp is far larger — about 24.6× Inovio Pharmaceuticals Inc's market cap, and Weibo Corp pays a 7.75% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WB | |
|---|---|---|
Market Cap | $78.55M | $1.93B |
Sector | Health | Media |
52-Week High | $2.87 | $12.83 |
52-Week Low | $0.66 | $7.20 |
Enterprise Value | $49.56M | $1.20B |
Dividend Yield | — | 7.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Weibo (WB) trades at $7.76, down 2.82% amid bearish technical signals, though valuation metrics appear attractive with a P/E of 5.5 and P/B of 0.5. The company maintains strong profitability with 21.15% net margins and $449M net income in 2025, but has missed earnings expectations for three consecutive quarters. Cash flow trends show volatility, with 2024 net cash flow negative $694M despite solid operational performance.
The stock presents a value opportunity given deep discount to balance sheet value, but faces competitive pressures and user engagement challenges. Analyst sentiment is mixed with 45% buy ratings, while technical indicators suggest near-term weakness. Key risks include Chinese regulatory environment and competition from Douyin/WeChat.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
